1 PM Stream Link: https://globalmeet.webcasts.com/starthere.jsp?ei=1665461&tp_key=b44e451330
6 PM Stream Link: https://globalmeet.webcasts.com/starthere.jsp?ei=1665472&tp_key=1eeea1e961
Add-on activity
This activity includes a Powered by Patients™ interview.
Program Description
Paroxysmal nocturnal hemoglobinuria (PNH) is a chronic, rare blood disorder in which a mutation in the X-linked PIGA gene leads to the early hemolysis of red blood cells. Consequences of hemolysis include thrombosis and organ damage, which contribute to the morbidity and mortality associated with PNH. In this first webinar in a 3-part series, pharmacists will become familiar with PNH pathophysiology and the role of the complement system in PNH pathogenesis. In addition, variability in patient presentation, diagnostic criteria, and impact on quality of life will be reviewed. A Powered by Patients™ interview will be included in the presentation to highlight the symptoms, diagnosis, and impact of PNH.
Target audience: Health-system and specialty pharmacists
Type of activity: Application
Release date: May 16, 2024
Expiration date: July 16, 2024
Time to complete activity: 1.0 hour
Learner level: Foundational; Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the clinical and economic impact of paroxysmal nocturnal hemoglobinuria (PNH) on patient morbidity, mortality, and overall disease progression
- Illustrate the complement pathway as it relates to target areas for the treatment of PNH
- Identify goals of therapy and the pertinent laboratory indicators, including the emerging landscape of biomarkers, to inform treatment decisions and enhance long-term patient outcomes
